Novosci: Connecting with Patients through Innovative healthcare products
President & CEO Dr. Nader Khedr explains the phenomenon of increased demand for new and innovative medications that meet patient's needs.
Can you give us an overview of the inception of NovoSci?
We have identified a gap in the pharmaceutical and healthcare markets, small to medium size companies are facing challenges in bringing their attractive range of products to the Middle East and Africa. The reasons are numerous, some of them being their lack of regional market understanding or the initial investment to enter the market. We have filled that gap and gave those companies a one-stop shop to access the Middle East and Africa markets through NovoSci Healthcare. Novosci started with two companies, and currently represents more than 30 international companies in the region. We already operate in 11 countries in Middle East and Africa. We have our own offices in the UAE, Egypt, Saudi, Algeria, South Africa and Kuwait.
Which divisions are a part of Novosci?
Novosci Group currently consists of two sister companies. NovoSci Healthcare that represents international companies in the region. Promopharma marketing company is a leading fostering and outsourcing powerhouse that manages co-promotion dealswith main pharmaceutical companies. We do outsourcing and fostering deals, sales, and promotion of around 35 million dollars in the Gulf from renowned multinational pharmaceutical companies.
A recently acquired company in the U.S, ConsuMED, will definitely add a lot in serving patient needs moto of NovoSci healthcare. ConuMED has a wide range of innovative consumer health brands, which will be in the region very soon.
What are your core areas of expertise?
We are mainly in six business units or therapy areas that includes Ophthalmology (Eye Care), Consumer Health, Women's health, Dermaceutical, anti-infective and pain management. The consumer health sector is booming in the Middle East and North Africa. Novosci is currently introducing innovative and new to market portfolio from Italy, Germany, and the U.S making us pioneers in many sub-categories.
Mention some products from your portfolio
At Novosci, our business development model is prioritising the patient needs by introducing advanced brands from the U.S and Europe. We are the first company to introduce Vitamin D3 with nanotechnology with very high absorption rates, Beta- Glucan and Vitamin K2. NovoSci is the first company to bring Ketoprofen patches to the region. Our diverse range includes appealing multi vitamins for the kids, meal replacement products for healthy and lean body, top of the range probiotics to increase immunity and health stomach, and many more. Our philosophy is to find attractive solutions for the patient that gives them optimum results.
What does the future hold for Novosci?
A vital milestone for Novosci, among many, has been our joint ventures in Algeria and South Africa. We aim to expand further into Africa, as we are already present in their largest markets. In this year, our goal is to access another 11 countries in Africa with a fantastic line of new products, which includes new class antibiotics, new line to treat hyper acidity, in addition to our Joint Venture with the biggest probiotics company in the world CHR Hansen will bring new full line of innovative probiotics formulas to the region.
As we step into the future of pharmaceuticals, it is imperative to bring new solutions to ease our patients life.
The temperature will rise to 35 degrees Celsius in Dubai and Abu Dhabi READ MORE
Successful handling of Covid-19 and achievements in science and... READ MORE
Authorities have blamed rule-breakers and unvaccinated people for the ... READ MORE
New MacBook Pro laptops with 14-inch and 16-inch displays are powered ... READ MORE